|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Methods:</b> A systematic search in electronic databases was performed to identify studies on selective estrogen receptor modulators (SERM) and down-regulators (SERD) and aromatase inhibitors that reported on response rates (RR) among EC patients.
|
31134155 |
2019 |
|
Malignant neoplasm of endometrium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Based on long-term adverse effects and complication safety data, when compared with tamoxifen, aromatase inhibitors are associated with a reduced incidence of thrombosis, endometrial cancer, and vaginal bleeding.
|
29794680 |
2018 |
|
Malignant neoplasm of endometrium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Adjusting for endometrial cancer risk factors, the A allele of rs4775936 in CYP19 was significantly associated (OR(per allele)=1.22, 95% CI=1.01-1.47, p(trend)=0.04), while the T allele of rs10046 was marginally associated with increased risk of endometrial cancer (OR(per allele)=1.20, 95% CI=0.99-1.45, p(trend)=0.06).
|
22633539 |
2012 |
|
Malignant neoplasm of endometrium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thus, CYP19 polymorphism might be one of the genetic risk factors for endometrial cancer development.
|
11216915 |
2001 |
|
Malignant neoplasm of endometrium
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of aromatase, estrogen receptors, and their coactivators in patients with endometrial cancer.
|
16730717 |
2006 |
|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that GFP expression is driven by estrogen synthesized by aromatase in the endometrial cancer stromal cells.
|
18508998 |
2008 |
|
Malignant neoplasm of endometrium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We hypothesized that the functional PPARgamma ProAla polymorphism may alter aromatase expression, ultimately affecting endometrial cancer susceptibility.
|
15608564 |
2004 |
|
Malignant neoplasm of endometrium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, increased risk of endometrial cancer with long-term tamoxifen administration and of bone fracture due to osteoporosis in postmenopausal women undergoing aromatase inhibitor therapy are recognized side effects.
|
17280616 |
2007 |
|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
In summary, we identified regions in AR and CYP19A1 that are of interest for further evaluation in relation to endometrial cancer risk in future haplotype and subsequent fine mapping studies in larger study populations.
|
20053928 |
2010 |
|
Malignant neoplasm of endometrium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Two estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium.
|
19124504 |
2009 |
|
Malignant neoplasm of endometrium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Second, molecular alterations in stromal cells favor binding of transcriptional enhancers versus inhibitors to a normally quiescent aromatase promoter and initiate transcription (breast/endometrial cancer, endometriosis, and uterine fibroids).
|
16109840 |
2005 |
|
Malignant neoplasm of endometrium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Linked variants in CYP19A1 (intron 4 [TTTA]n, intron 4 [TCT] insertion/deletion, exon 10 C/T) are related to some hormone levels and, based on two studies, to risk of endometrial cancer.
|
17110639 |
2007 |
|
Malignant neoplasm of endometrium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that there is a high-frequency CYP19 haplotype related to higher estrogen to androgen ratios and increased risk of endometrial cancer and that this association may primarily pertain to postmenopausal women.
|
15800924 |
2005 |
|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, positive correlation between CYP19A1 and LPAR1 accounts for supporting role of LPA acting via LPAR1 in intratumoral DHT concentration and the ethiology of endometrial cancer progression.
|
29182028 |
2018 |
|
Malignant neoplasm of endometrium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Based on long-term adverse effects and complication safety data, when compared with tamoxifen, aromatase inhibitors are associated with a reduced incidence of thrombosis, endometrial cancer, and vaginal bleeding.
|
29794673 |
2018 |
|
Malignant neoplasm of endometrium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The primary aim of our study was to investigate the incidence of endometrial pathologies, especially endometrial cancer, in women with breast cancer treated with tamoxifen (TAM), aromatase inhibitors (AIs), or receiving no treatment (NT).
|
31425735 |
2019 |
|
Malignant neoplasm of endometrium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We found no significant association between CYP19A1 genotypes and haplotypes and endometrial cancer risk.
|
22320986 |
2011 |
|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aromatase inhibitor (AI) drugs are used in the treatment of both diseases, however, response rates for AIs are low and there is currently no way to identify breast or endometrial cancer patients who are more likely to receive a clinical benefit.
|
28487654 |
2017 |
|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, although type II of EC is frequently considered as hormone-independent, increased ability of this type of the tumor to estrogen biosynthesis (at CYP19 gene and protein level) may lead to the reconsideration of such conclusion and warrants further investigation.
|
15939586 |
2005 |
|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Contradictory results are reported about the level of steroid sulfatase (STS), estrogen sulfotransferase (SULT1E1; together, the sulfatase pathway) and aromatase (CYP19A1) in endometrial cancer (EC).
|
30217785 |
2018 |
|
Malignant neoplasm of endometrium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the present work the distribution of genotypes and frequency of alleles of the C/T polymorphism in promoter region of CYP17 and G/A polymorphism at position Val80 in CYP19 in subjects with endometrial cancer were investigated.
|
17167982 |
2006 |
|
Malignant neoplasm of endometrium
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To the best of our knowledge, this is the first evidence associating intratumoral aromatase expression in stromal cells and poor survival in endometrioid endometrial cancer.
|
15788666 |
2005 |
|
Malignant neoplasm of endometrium
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Altered expression of ERs, aromatase, and COX2 connected to estrogen action in type 1 endometrial cancer biology.
|
23873111 |
2013 |
|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our result, although needs further investigation on the cause of the difference from other studies, suggested that aromatase might not have an important role in endometrial cancer.
|
17404019 |
2007 |
|
Malignant neoplasm of endometrium
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To correct this gap we studied aromatase activity and gene expression totally in 19 samples of EC (17 of them -- from postmenopausal women) collected during surgery.
|
15800709 |
2005 |